title: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
abstract: OBJECTIVE
  To assess the clinical relevance of serum secretory leukocyte protease inhibitor (SLPI) levels in distinguishing patients with ovarian cancers from those with benign ovarian cysts, we determined concentrations with reference to the FIGO stage and other clinical characteristics.
  
  
  METHODS
  Preoperative serum SLPI levels were measured in women with invasive epithelial ovarian cancer (n = 55), benign ovarian cysts (n = 25), or normal controls (n = 38) using an enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  The serum SLPI concentration was significantly elevated in the ovarian cancer patients (median 67 ng/ml, interquartile range 26-124 ng/ml) as compared to the benign cyst patients (37 and 25-66 ng/ml) or healthy women (32 and 25-43 ng/ml). Using an SLPI cutoff of 50 ng/ml and a CA125 cutoff of 30 units/ml, with both markers elevated the sensitivity was 95%, the specificity was 100%, the positive predictive value was 100%, and the negative predictive value was 89% between the malignant and benign cyst patients.
  
  
  CONCLUSIONS
  Serum SLPI levels could be useful for differentiating benign ovarian cysts from malignancies and to improve the specificity of diagnosis.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya City University Graduate School of Medicine, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
authors.forename: Sami
authors.initials: S
authors.lastname: Tsukishiro
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Suzumori
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Arakawa
authors.forename: Kaoru
authors.initials: K
authors.lastname: Suzumori
mesh_terms: D018394:CA-125 Antigen / Q000097:blood; D016022:Case-Control Studies; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010048:Ovarian Cysts / Q000097:blood / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000378:metabolism*; D053481:Secretory Leukocyte Peptidase Inhibitor; D012680:Sensitivity and Specificity
chemical_list: D018394:CA-125 Antigen; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor